Engelmann, J.
Zillich, L. http://orcid.org/0000-0001-7457-374X
Frank, J. http://orcid.org/0000-0003-4867-9465
Wagner, S.
Cetin, M.
Herzog, D. P.
Müller, M. B. http://orcid.org/0000-0002-0269-6131
Tadic, A.
Foo, J. C. http://orcid.org/0000-0003-1067-5725
Sirignano, L. http://orcid.org/0000-0002-7989-5833
Braus, D. F.
Dahmen, N.
Sordon, S.
Riemenschneider, M.
Spaniol, C.
Gasparoni, G.
Rietschel, M. http://orcid.org/0000-0002-5236-6149
Witt, S. H. http://orcid.org/0000-0002-1571-1468
Lieb, K.
Streit, F. http://orcid.org/0000-0003-1080-4339
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (01EW1904, 01 KG 0906)
Article History
Received: 23 January 2022
Revised: 14 June 2022
Accepted: 17 June 2022
First Online: 7 July 2022
Competing interests
: A Tadic is designated as inventor of the European patent number 12171541.1–2404 ‘Method for predicting response or non-response to a mono-aminergic antidepressant’. He has received during the last five years consultancy fees from Janssen, Novartis, and ROVI. K Lieb is designated as inventor of the European patent number 12171541.1–2404 ‘Method for predicting response or non-response to a mono-aminergic antidepressant’. DF Braus has received in the last 5 years fees for unrestricted educational lectures from Lilly, Janssen, Bayer, Lundbeck, Servier, Shire, TAD Pharma, Lundbeck, Berlin-Chemie, Takeda, Rovi, Biogen, MSD. The remaining authors declare no competing interests.